Medco
Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
Premium
Roche made a splash last year with its repeated overtures to acquire genome sequencing firm Illumina, but for the most part, 2012 was a quiet year during which players in the life sciences industry took modest steps to increase their capabilities to advance personalized treatment
Illumina announced that Robert Epstein has joined its board of directors. Epstein formerly was chief R&D officer and president of Medco-UBC, and he was Medco’s chief medical officer for 13 years.
Third Rock Ventures has hired Felix Frueh as an entrepreneur-in-residence.
Originally published Aug. 23.
New Firm MetaDiagnostic Moves in to Help Dx Developers, Payors as PBMs Shift from Personalized Rx
Premium
Originally published Aug. 27.
Jan 18, 2012
Oct 26, 2011
Oct 26, 2011
Pfizer, Medco Team on 'Precision Medicine' Effort
Oct 19, 2011
Jun 29, 2011